Gene Editing by Ferrying of CRISPR/Cas Ribonucleoprotein Complexes in Enveloped Virus-Derived Particles

Hum Gene Ther. 2024 Sep;35(17-18):604-616. doi: 10.1089/hum.2024.105. Epub 2024 Aug 27.

Abstract

The invention of next-generation CRISPR/Cas gene editing tools, like base and prime editing, for correction of gene variants causing disease, has created hope for in vivo use in patients leading to wider clinical translation. To realize this potential, delivery vehicles that can ferry gene editing tool kits safely and effectively into specific cell populations or tissues are in great demand. In this review, we describe the development of enveloped retrovirus-derived particles as carriers of "ready-to-work" ribonucleoprotein complexes consisting of Cas9-derived editor proteins and single guide RNAs. We present arguments for adapting viruses for cell-targeted protein delivery and describe the status after a decade-long development period, which has already shown effective editing in primary cells, including T cells and hematopoietic stem cells, and in tissues targeted in vivo, including mouse retina, liver, and brain. Emerging evidence has demonstrated that engineered virus-derived nanoparticles can accommodate both base and prime editors and seems to fertilize a sprouting hope that such particles can be further developed and produced in large scale for therapeutic applications.

Keywords: CRISPR/Cas; Lentivirus-derived nanoparticles; gene correction; lentivirus; retrovirus; ribonucleoprotein; virus-like particle.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • CRISPR-Cas Systems*
  • Gene Editing* / methods
  • Gene Transfer Techniques
  • Genetic Therapy / methods
  • Genetic Vectors / genetics
  • Humans
  • RNA, Guide, CRISPR-Cas Systems / genetics
  • Retroviridae / genetics
  • Ribonucleoproteins* / genetics
  • Ribonucleoproteins* / metabolism
  • Virion / genetics
  • Virion / metabolism

Substances

  • Ribonucleoproteins
  • RNA, Guide, CRISPR-Cas Systems